Analysis: Big brain projects highlight drug research gaps | Reuters
Governments on both sides of the Atlantic are placing big new bets on the future of brain science, just as much of the pharmaceutical industry retreats from the field.
Brain disorders ranging from depression to Alzheimer's are extracting an ever greater social and economic cost across the globe. But while the United States and European Union are funding ambitious efforts in neuroscience, the private sector is often skeptical about the prospect of rapid breakthrough cures.
Many pharmaceutical companies harbor deep doubts about whether neuroscience is worth their investment dollars as a boom period for once highly profitable psychiatric medicines comes to an end and new drugs prove hard to find.